Vireo Growth (VREOF) Interest Expenses (2020 - 2026)
Vireo Growth (VREOF) reported Interest Expenses of $258.9 million for Q1 2026, up 3306.8% on a YoY basis from $7.6 million in Q1 2025, and up 3328.67% sequentially from $7.6 million in Q4 2025.
Vireo Growth (VREOF) Interest Expenses (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Interest Expenses data on file, last reported at $258.9 million in Q1 2026.
- For the quarter ending Q1 2026, Interest Expenses rose 3306.8% year-over-year to $258.9 million; the trailing twelve-month figure through Mar 2026 stood at $258.9 million (up 436.56% YoY), and the FY2025 full-year result was $28.6 million, down 10.45% from the prior year.
- Interest Expenses grew to $258.9 million in Q1 2026, from $7.6 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $283.0 million in Q2 2024 to a low of $6.8 million in Q4 2023.
- A 5-year average of $74.7 million and a median of $16.2 million in 2022 frame the typical range for Interest Expenses.
- Across the five-year window, Interest Expenses plunged 96.46% in 2022 and jumped 3511.12% in 2025, its largest moves.
- Tracing VREOF's Interest Expenses over 5 years: stood at $7.1 million in 2022, then fell by 5.19% to $6.8 million in 2023, then surged by 293.1% to $26.5 million in 2024, then tumbled by 71.55% to $7.6 million in 2025, then surged by 3328.67% to $258.9 million in 2026.
- Business Quant data shows VREOF's Interest Expenses at $258.9 million in Q1 2026, $7.6 million in Q4 2025, and $265.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 944.51 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.77 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 2.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.21 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 590.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 258.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 258.90 Mn |
| Mar 31, 2026 | 258.90 Mn |
| Dec 31, 2025 | 7.55 Mn |
| Dec 31, 2025 | 7.55 Mn |
| Sep 30, 2025 | 265.91 Mn |
| Sep 30, 2025 | 265.91 Mn |
| Jun 30, 2025 | 61.05 Mn |
| Jun 30, 2025 | 61.05 Mn |
| Mar 31, 2025 | 7.60 Mn |
| Mar 31, 2025 | 7.60 Mn |
| Dec 31, 2024 | 26.54 Mn |
| Dec 31, 2024 | 26.54 Mn |
| Sep 30, 2024 | 7.36 Mn |
| Sep 30, 2024 | 7.36 Mn |
| Jun 30, 2024 | 282.96 Mn |
| Jun 30, 2024 | 282.96 Mn |
| Mar 31, 2024 | 20.00 Mn |
| Mar 31, 2024 | 20.00 Mn |
| Dec 31, 2023 | 6.75 Mn |
| Dec 31, 2023 | 6.75 Mn |